New hope for advanced breast cancer patients Who've exhausted other options
NCT ID NCT07480694
Summary
This study examines how well eribulin-based treatments work for advanced HER2-negative breast cancer patients who have already received antibody-drug conjugate therapies. Researchers will follow 400 patients who receive eribulin treatment after their previous treatments. The main goal is to measure how long patients live without their cancer getting worse while on this treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT EFFICACY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.